{Reference Type}: Journal Article
{Title}: Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
{Author}: Girardi M;Carlson K;Huang X;Corman SL;Edmundson P;Schmier J;Kale HP;Raina R;Foss F;
{Journal}: J Dermatolog Treat
{Volume}: 35
{Issue}: 1
{Year}: 2024 Dec
{Factor}: 3.23
{DOI}: 10.1080/09546634.2024.2360568
{Abstract}: <B>UNASSIGNED: </B>Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of extracorporeal photopheresis (ECP) in CTCL patients.<BR><B>UNASSIGNED: </B>A chart review was conducted in the United States of adults with CTCL who initiated ECP between January 1, 2017, and February 28, 2019, and received at least three months of ECP treatment as monotherapy or concomitant therapy. Clinical outcomes were collected quarterly for up to 18 months.<BR><B>UNASSIGNED: </B>The 52 patients were predominantly Caucasian. Half were male; median age was 69 years. Most patients had Sézary syndrome (50%) or mycosis fungoides (36.5%). Nearly 40% of patients had stage IV disease; 33% had lymph node involvement. Nineteen patients (36.5%) achieved response (>50% reduction in BSA affected); median time to response was 6.5 months. The percentage of patients rated as at least minimally improved was 59.5% at 6 months (N = 22), 75.0% at 9 months (N = 24), and 60.0% at 12 months (N = 15) after ECP initiation.<BR><B>UNASSIGNED: </B>Despite the ECP treated population in this study being older and having more advanced-stage disease than recent trials, response rates were comparable. These real-world findings support ECP as an effective treatment option for CTCL patients.